Challenge in treating COVID-19 associate pulmonary aspergillosis: Supratherapeutic voriconazole levels

Creative Commons License

Bakir Ekinci P., Kara E., Er A. G., İnkaya A. Ç., Demirkan K., Uzun Ö.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, cilt.88, sa.3, ss.1387-1391, 2022 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Kısa Makale
  • Cilt numarası: 88 Sayı: 3
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1111/bcp.14953
  • Dergi Adı: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.1387-1391
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

Sir, There is a cumulative evidence suggesting COVID-19 victims are prone to COVID-19 associated pulmonary aspergillosis (CAPA). COVID-19 itself and immunomodulatory medications, such as corticosteroids and tocilizumab, compromise the immune system to an extent that opportunistic infections complicate the course further. In this letter, we aimed to highlight the relationship between inflammation and voriconazole trough levels in COVID-19 patients.